KBio Announces FDA Clearance of IND Application for EV68-228-N for the Treatment of Acute Flaccid Myelitis and the First Patient Dosed in the Phase 1 Study • The United States Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application for EV68-228-N, a human monoclonal IgG1 against the capsid of enterovirus D68 (EV-D68)...

KBio and ZERO Announce Exclusive Strategic Alliance to Develop a Globally Distributed and Rapidly Deployable Plant-Based Molecular Farming Network LONDON and VENICE, Italy, Aug. 01, 2023 (GLOBE NEWSWIRE) -- KBio, one of the leading developers of new biological treatments derived from a plant-based production system, and ZERO, an Italian agtech...

KBio Announces Strategic Collaboration with Leaf Expression Systems to Enhance Development and Production of Novel Therapeutics LONDON, Sept. 28, 2022 (GLOBE NEWSWIRE) -- KBio, a leading developer of new biological treatments derived from a plant-based production system, today announced the formation of a strategic...

KBio Announces Strategic Partnership with ZabBio to Discover and Develop Antibody Therapeutics Agreement combines drug discovery and plant-based platform expertise to accelerate discovery and development of a new generation of biologics-based medicines for areas of high unmet need KBio...

KBio Appoints Sean Stevens, Ph.D. as Chief Scientific Officer LONDON, May 05, 2022 (GLOBE NEWSWIRE) -- KBio, a leading developer of new biological treatments derived from a plant-based production system, today announced the appointment of Sean Stevens, Ph.D....